

Is Carvedilol still hard to find in 2026? Get the latest on supply status, pricing, and what you can do if your pharmacy is out of stock.
If you've had trouble filling your Carvedilol prescription recently, you're probably wondering: is there an actual shortage? The short answer is that Carvedilol is not on the FDA or ASHP drug shortage lists as of early 2026. But that doesn't mean every pharmacy has it on the shelf.
Many patients across the country have reported sporadic difficulty finding Carvedilol — particularly certain strengths and formulations. In this update, we'll explain what's really happening with Carvedilol supply in 2026, what it costs, and what you can do to stay on your medication.
Technically, no. Carvedilol is not classified as being in a nationwide shortage. The FDA and ASHP (American Society of Health-System Pharmacists) maintain official shortage lists, and Carvedilol is not currently on either one.
However, there's an important distinction between a formal shortage and real-world availability problems. Even when a drug isn't officially in shortage, individual pharmacies can run out due to:
So if your pharmacist tells you they can't get Carvedilol right now, they're not making it up — it's just a localized supply issue rather than a national one.
For a detailed breakdown, read our full article on why Carvedilol is hard to find in 2026. Here's the summary:
Carvedilol is manufactured by multiple generic companies including Teva, Aurobindo, Zydus, and Sun Pharma. The generic drug supply chain has faced persistent challenges since 2022, including raw material sourcing difficulties, quality control shutdowns, and manufacturing consolidation. When even one major manufacturer has a production delay, pharmacies that rely on that supplier can run dry.
Not all Carvedilol strengths are equally available. Lower strengths like 3.125 mg and 6.25 mg (used for initial dosing and titration) are sometimes harder to find because pharmacies stock them less frequently. The extended-release version (Coreg CR) and its generic equivalents have more limited manufacturer availability overall.
Large chain pharmacies use automated inventory systems that may not keep your specific strength in stock if it's not regularly dispensed at that location. Independent pharmacies often have more flexible ordering and may be able to source your medication more readily.
The cost of Carvedilol depends on whether you're buying generic or brand-name, and whether you have insurance or use a discount card:
For all the ways to bring your costs down, see our guide on how to save money on Carvedilol in 2026.
A few developments worth knowing about in 2026:
If your pharmacy is out, try these steps:
For the full playbook, read how to find Carvedilol in stock near you.
If Carvedilol is truly unavailable in your area for an extended period, talk to your doctor about alternative medications. The most common substitutes include:
Critical reminder: Do not stop Carvedilol abruptly. Sudden discontinuation can cause rebound tachycardia, blood pressure spikes, and increased risk of cardiac events. Always taper under your doctor's guidance.
While Carvedilol isn't in a formal nationwide shortage in 2026, individual pharmacies may still run out from time to time. The best thing you can do is plan ahead: use Medfinder to track availability, refill early, and keep your doctor informed about any access issues.
Carvedilol is an effective, affordable medication with a long track record of helping people with heart failure and high blood pressure. With a little planning, you can make sure it stays part of your treatment routine.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.